Page last updated: 2024-12-06
fenethazine
Description
Fenethazine is a phenothiazine derivative that has been investigated for its potential antipsychotic and antiemetic effects. It was synthesized in the 1950s and has shown some activity in preclinical studies, but it has not been widely used clinically. Studies on fenethazine have focused on its pharmacological properties, particularly its affinity for dopamine receptors, and its potential therapeutic applications. However, the research on fenethazine has been limited and further investigation is needed to fully understand its potential benefits and risks.'
fenethazine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 68223 |
| CHEMBL ID | 2106299 |
| CHEBI ID | 135112 |
| SCHEMBL ID | 144367 |
| MeSH ID | M0063129 |
Synonyms (46)
| Synonym |
|---|
| fenethazine |
| 10h-phenothiazine-10-ethanamine, n,n-dimethyl- |
| 522-24-7 |
| D02602 |
| fenethazine (inn) |
| einecs 208-325-1 |
| etisine |
| phenethazine |
| fenetazina [dcit] |
| anergen |
| 10-(beta-dimethylaminoethyl)phenothiazine |
| phenethazinum |
| ethysene |
| 10-(2-dimethylaminoethyl)phenothiazine |
| n,n-dimethyl-10h-phenothiazine-10-ethanamine |
| sc 1627 |
| fenethazinum [inn-latin] |
| etisin |
| anergell |
| rp 3015 |
| fenethazine [inn:dcf] |
| ethysine |
| lisergan |
| ethyzine |
| phenetazine |
| phenothiazine, 10-(2-(dimethylamino)ethyl)- |
| rutergan |
| lysergan |
| ethizine |
| NCIOPEN2_007228 |
| CHEBI:135112 |
| n,n-dimethyl-2-phenothiazin-10-ylethanamine |
| unii-8j97cuz4hx |
| 8j97cuz4hx , |
| fenethazinum |
| fenethazine [inn] |
| fenethazine [who-dd] |
| fenethazine [mi] |
| CHEMBL2106299 |
| SCHEMBL144367 |
| DTXSID30200233 |
| n,n-dimethyl-2-phenothiazin-10-yl-ethanamine |
| Q21098990 |
| rp 3015; rutergan; sc 1627 |
| n,n-dimethyl-2-(10h-phenothiazin-10-yl)ethan-1-amine |
| AKOS040746825 |
Drug Classes (1)
| Class | Description |
|---|
| phenothiazines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 4 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |